Several biomarkers deserve attention throughout the protocol
For those of us in metabolic health, the "triple agonist" (GGG) mechanismtargeting GLP-1, GIP, and Glucagon receptorshas long been the theoretical "holy grail." The idea is to not just suppress appetite (GLP-1/GIP) but to also increase energy expenditure (Glucagon)
In our present study, RJ pretreatment reversed this effect, indicating that RJ may be a potent antioxidant against Cd-induced nephrotoxicity by modulating the expression of antioxidant and detoxification enzymes
The ability to support multi-dose use makes bacteriostatic water an efficient and practical choice for ongoing research protocols
Salama, V
Whether the spectacular preclinical pharmacology of GLP-1R/GcgR co-agonists will translate through successful phase 3 registration trials is a question that will be answered in the coming years, but the pursuit of multifunctional, targeted therapeutics is destined to continue